Trifluridine

曲氟尿苷

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameTrifluridine
Drug Alias Nametrifluridina曲氟胸苷Trifluridinum屈氟尿苷三氟哩啶 +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsSolid tumoursKeratoconjunctivitisLiver Neoplasms +[8] 
Global Approved IndicationsKeratoconjunctivitisKeratitis, Herpetic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1980/04/10
Country/TerritoryUnited StatesThailandSouth Korea +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoMonarch Pharmaceuticals Llc
Inactive CompaniesNational Cancer InstituteTaiho Pharmaceutical Co LtdTaiho Oncology Inc
Active IndicationsKeratoconjunctivitisLiver NeoplasmsRectal Neoplasms +[5] 
Inactive IndicationsSolid tumoursColorectal NeoplasmsOsteosarcoma

Other Information

ATC CodeS01AD02
Related LinksWikipediaDrugBankKEGG